Modern product development demands a new playbook for non-clinical safety, one that is agile, predictive, and aligned with both innovation and regulation. This symposium introduces a suite of contemporary strategies for optimising safety assessment across diverse modalities, including biologics, gene therapies, and novel delivery systems. Topics include the use of exposure-response modelling, platform-based toxicology, and translational biomarkers to inform smarter go/no-go decisions.

Attendees will gain practical insights into building safety strategies that are not only scientifically robust but also developmentally efficient.

This event is kindly sponsored by...

Agenda:
•    13:30 – 14:00 - Arrival and Registration with Tea/Coffee/Biscuits
•    14:00 – 14:10 - Opening Remarks, welcome and introduction – Lee A. Coney, Chief Scientific Officer
•    14:10 – 14:55 - How Do We Design, Execute, And Report Complex Studies? – Presented by Charlotte Mann, Toxicology Team Leader
•    14:55 – 15.40 – Non-Clinical Strategies to meet development milestones for successful fundraising or partnering – Presented by Lee A. Coney, Chief Scientific Officer
•    15:40 – 16:10 - Cream Tea 
•    16:10 – 16:55 - The Evolution of Regulatory Expectations in Developmental and Reproductive Toxicity (DART) Testing – Presented by Frances Tyler-James, Toxicologist
•    16:55 – 17:00 - Final remarks – Lee A. Coney
•    17:00 – 18:00 - Networking Drinks
•    18:00 - Close

Registration: This event is free to attend and invite only. To request an invite, please contact [email protected] at your earliest convenience.